GSK PLC Reports Quarterly Earnings

GSK PLC, a pharmaceutical company in the Health Care sector, has released its quarterly earnings report. Key highlights from the report include:

• Revenue: £7.52 billion, representing a 2.08% increase from the previous year.
• Vaccine sales: Declined by 6% compared to the same period in the previous year.
• Specialty medicines sales: Increased by 17% compared to the same period in the previous year.

Product Development

GSK has reported positive trial results for its treatment Nucala in chronic obstructive pulmonary disease (COPD). The trial demonstrated a clinically meaningful reduction in exacerbations.

Stock Performance

GSK’s stock price has been fluctuating. Notable developments include a move into the 80-plus level on its Relative Strength Rating.

Key Statistics

• Revenue growth: 2.08%
• Vaccine sales decline: 6%
• Specialty medicines sales growth: 17%